2019-11-12T16:39:21-06:00 2018-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2018-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 BRIAN NEVILLE CHIEF OF ACCOUNTING 2062853500 2019-11-12 1 RICHARD J LOCASTRO CPA P00288314 3019519090 75.103.231.202 2019-11-12 17:39:17 ES P 981DD7ACBC606C3C3562579832A13CC83ACA1B41 60F5620986AF14763908AFE7AC6F4ECEC523E148 2018 2020-03-31 21:24:44Z BRIAN NEVILLE 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 46072079 0 X WWW.PATH.ORG X 2006 WA SEE PART III, LINE 1. 7 2 0 0 0 0 6592045 34948159 0 0 504329 844490 12542 14669 7108916 35807318 30367803 23787777 0 0 0 0 0 0 0 13366543 11603798 43734346 35391575 -36625430 415743 66391789 38472788 14042965 37875254 52348824 597534 X THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-INCOME COUNTRIES BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST.FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT.PVS WORKS WITH PARTNERS TO DEVELOP NEW VACCINES BY PROVIDING FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE COUNTRIES. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN LOW AND MIDDLE-INCOME COUNTRIES. 0 0 35391575 23787777 PVS WORKS TO PREVENT DEATH AND DISEASE CAUSED BY DIARRHEA, PNEUMONIA, INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS, AND POLIO AMONG CHILDREN AROUND THE WORLD. WE ACCELERATE THE DEVELOPMENT OF SAFE, EFFICACIOUS, AND AFFORDABLE VACCINES IN PARTNERSHIP WITH PUBLIC AND PRIVATE GROUPS. IN 2018, PVS CONTINUED OUR FIGHT AGAINST DIARRHEAL DISEASES, THE SECOND LEADING CAUSE OF DEATH AMONG CHILDREN IN LOW-INCOME COUNTRIES. TO COMBAT ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, WE CONTINUED CLINICAL DEVELOPMENT OF A NONREPLICATING ROTAVIRUS VACCINE CANDIDATE, INCLUDING PLANNING FOR A LATE-STAGE EFFICACY STUDY. THIS VACCINE CANDIDATE IS ADMINISTERED AS AN INTRAMUSCULAR INJECTION AND COULD POTENTIALLY OVERCOME THE LOWER EFFICACY LEVELS SEEN IN LOW-RESOURCE SETTINGS FOR ORAL, LIVE ATTENUATED VACCINES. IN ADDITION, PVS SUPPORTED BHARAT BIOTECH AND SERUM INSTITUTE OF INDIA PVT. LTD. (SIIPL) IN ACHIEVING WORLD HEALTH ORGANIZATION PREQUALIFICATION OF THEIR ROTAVIRUS VACCINES. BHARAT'S ROTAVAC WAS PREQUALIFIED IN JANUARY 2018, AND SIIPL'S ROTASIIL WAS PREQUALIFIED IN SEPTEMBER 2018. IN ADDITION, PVS HOSTED A MEETING IN NOVEMBER 2018 IN NEW DELHI FOR MAJOR STAKEHOLDERS TO EVALUATE THE EVIDENCE BASE FOR MEASURING THE OVERALL PUBLIC HEALTH IMPACT AND BENEFIT OF ROTAVIRUS VACCINES IN INDIA.PVS CONTINUED TO CONDUCT EARLY STAGE CLINICAL TRIALS OF VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, LEADING CAUSES OF BACTERIAL DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. IN ADDITION, WE HELD THE SECOND INTERNATIONAL VACCINES AGAINST SHIGELLA AND ETEC (VASE) CONFERENCE IN JUNE 2018 IN MEXICO CITY, WHICH BROUGHT TOGETHER NEARLY 200 GLOBAL DONORS, SCIENTISTS, AND OTHER EXPERTS TO DISCUSS DEVELOPING AND INTRODUCING NEW ENTERIC VACCINES.WE ALSO ADVANCED DEVELOPMENT OF LOW-COST VACCINE CANDIDATES TO PROTECT CHILDREN AGAINST PNEUMOCOCCAL BACTERIA, THE TOP CAUSE OF SEVERE CHILDHOOD PNEUMONIA. IN 2018, WE COMPLETED THE VACCINATION COMPONENT AND BEGAN THE IMMUNE PERSISTENCE COMPONENT OF A PHASE 3 STUDY IN THE GAMBIA TO EVALUATE A PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10) CANDIDATE. THIS CANDIDATE IS DESIGNED TO BE AFFORDABLE AND TO PROVIDE PROTECTION AGAINST TEN BACTERIAL SEROTYPES THAT CAUSE MOST CASES OF INVASIVE PNEUMOCOCCAL DISEASE IN AFRICA AND ASIA.IN 2018, AS PART OF THE ADVANCING MATERNAL IMMUNIZATION COALITION, WE PUBLISHED AN ANALYSIS IDENTIFYING ESSENTIAL GAPS IN THE INFORMATION AND CONDITIONS NEEDED TO SUPPORT DECISION-MAKING ON MATERNAL IMMUNIZATION WITH A FUTURE RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE. WE ALSO PUBLISHED A ROAD MAP THAT, BASED ON THE GAP ANALYSIS, OUTLINES ACTIVITIES THAT MUST BE COMPLETED FOR RSV MATERNAL IMMUNIZATION DECISION-MAKING AND DELIVERY TO MOVE FORWARD. 35391575 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X BRIAN NEVILLE CHIEF OF ACCOUNTING 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS CHAIR AND PRESIDENT 1.00 39.00 X X 0 665877 62780 ANITA ZAIDI VICE CHAIR 1.00 0.00 X X 0 0 0 OLIVIA D POLIUS TREASURER 1.00 39.00 X X 0 320646 51936 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 310669 41544 AMIE E BATSON DIRECTOR 1.00 39.00 X 0 378150 22577 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 379045 65678 CHRIS KARP DIRECTOR 1.00 0.00 X 0 0 0 0 2054387 244515 0 0 1 0 0 34948159 34948159 793638 793638 10315613 10264761 50852 50852 50852 MISCELLANEOUS 900099 11425 11425 OTHER REIMBURSEMENTS 900099 3244 3244 14669 35807318 0 0 859159 22084256 22084256 1703521 1703521 13886 13886 73916 73916 572542 572542 3294 3294 203169 203169 31216 31216 50000 50000 782318 782318 109959 109959 14916 14916 35313 35313 SUBCONTRACTORS 9422835 9422835 LAB SUPPLIES 197948 197948 STORAGE 63179 63179 EQUIPMENT R&M 23914 23914 5393 5393 35391575 35391575 0 0 1111 21866566 814380 56033 -14 294849 251578 24348 43271 44444842 37614040 66391789 38472788 14042965 37875254 14042965 37875254 X 8544 118341 52340280 479193 52348824 597534 66391789 38472788 X 415743 76618 -52243651 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 35391575 0 1 35391575 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 294849 251578 43271 43271 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 172953 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 33831 EUROPE 0 1 PROGRAM SERVICES ESSENTIAL MEDICINE 1877844 EUROPE 0 0 GRANTMAKING 2008249 NORTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 173836 SOUTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 42539 SOUTH ASIA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 31306 SOUTH ASIA 0 0 GRANTMAKING -598280 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 200092 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 259721 0 1 0 0 0 1 3742278 459813 4202091 EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 33831 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 14007 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 18017 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 37772 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 65000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 146770 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 182850 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 184654 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 780000 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 259720 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE -542256 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE -56024 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 579180 CHECK/WIRE 9 4 1 0 0 0 0 0 PART I, LINE 2: PVS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PVS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 1 TULANE UNIVERSITY 6823 ST CHARLES AQGE NEW ORLEANS LA 701122632 720423889 501(C)(3) 22000 ESSENTIAL MEDICINE ADVANCED BIOSCIENCE LABORATORIES INC 9800 MEDICAL CENTER DRIVE BUILDING D ROCKVILLE MD 20850 621242262 N/A 24550 ESSENTIAL MEDICINE GLOBAL ALLI TO PREV PREMATURITY & STILLBIRTH SEA CHILD HOSP 4800 SAND PT WAY NE PO BOX 5371 SEATTLE WA 981455005 910564748 501(C)(3) 26465 ESSENTIAL MEDICINE KANSAS STATE UNIVERSITY 2 FAIRCHILD HALL MANHATTAN KS 665061103 480771751 501(C)(3) 30000 ESSENTIAL MEDICINE LANKENAU INSTITUTE FOR MEDICAL RESEARCH 100 LANCASTER AVE WYNNEWOOD PA 190963450 232175659 501(C)(3) 35000 ESSENTIAL MEDICINE WASHINGTON UNIVERSITY IN ST LOUIS CAMPUS BOX 1034 700 ROSEDALE AVE ST LOUIS MO 631121408 430653611 501(C)(3) 40429 ESSENTIAL MEDICINE UNIVERSITY OF ALABAMA GRANTS CONTRACTS ACCT AV 990 1720 2ND AVE S BIRMINGHAM AL 352940109 636005396 501(C)(3) 54526 ESSENTIAL MEDICINE FOOD AND DRUG ADMINISTRATION 5600 FISHERS LN HFA-140 RM 11-40 ROCKVILLE MD 20857 530196965 GOV 60000 ESSENTIAL MEDICINE CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVE ML 6014 CINCINNATI OH 452293039 310833963 501(C)(3) 107620 ESSENTIAL MEDICINE THE UNIVERSITY OF FLORIDA PO BOX 113201 GAINESVILLE FL 326113201 596002052 501(C)(3) 129149 ESSENTIAL MEDICINE CHILDREN'S HOSPITAL BOSTON RESEARCH FINANCE PO BOX 414413 BOSTON MA 022414413 042774441 501(C)(3) 155000 ESSENTIAL MEDICINE HENRY M JACKSON FDN FOR THE ADVANCEMENT OF MILITARY MEDICINE INC 6720-A ROCKLEDGE DR STE 100 BETHESDA MD 20817 521317896 501(C)(3) 160712 ESSENTIAL MEDICINE JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHL OF PUB HLTH 615 N WOLFE STREET BALTIMORE MD 21205 520595110 501(C)(3) 379105 ESSENTIAL MEDICINE WALTER REED ARMY INSTITUTE OF RESEARCH US TREASURY 503 ROBERT GRANT AVE SILVER SPRING MD 209107500 520664528 GOV 420861 ESSENTIAL MEDICINE UNIVERSITY OF MARYLAND PO BOX 41428 BALTIMORE MD 212036425 526002033 501(C)(3) 506014 ESSENTIAL MEDICINE PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 20062779 ESSENTIAL MEDICINE INFECTIOUS DISEASE RESEARCH INSTITUTE 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 911608978 501(C)(3) -132489 ESSENTIAL MEDICINE FAMILY HEALTH INTERNATIONAL (FHI 360) 2224 EAST NC HWY 54 DURHAM NC 277132208 832853562 501(C)(3) -465 ESSENTIAL MEDICINE US NAVAL MEDICAL RESEARCH UNIT 3 NAMRU-3 503 ROBERT GRANT AVE BLDG 500 SILVER SPRING MD 20901 470100048 GOV 3000 ESSENTIAL MEDICINE 18 1 PART I, LINE 2: PVS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PVS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS CHAIR AND PRESIDENT 0 512010 0 152067 0 1800 0 32200 0 30580 0 728657 0 0 OLIVIA D POLIUS TREASURER 0 318546 0 0 0 2100 0 32400 0 19536 0 372582 0 0 DANIEL LASTER SECRETARY 0 308869 0 0 0 1800 0 32400 0 9144 0 352213 0 0 AMIE E BATSON DIRECTOR 0 194527 0 0 0 183623 0 21347 0 1230 0 400727 0 0 DAVID C KASLOW DIRECTOR 0 377245 0 0 0 1800 0 32400 0 33278 0 444723 0 0 PART I, LINE 3 PVS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG AND FREEDMAN CPAS), USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PVS'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PVS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PVS BOARD MEMBERS AND OFFICERS MUST ANNUALLY COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM. PVS DOES NOT HAVE EMPLOYEES. PVS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF INTERNAL REVENUE CODE SECTION 509(A)(3) AND CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF AT HIGHER THAN A DESIGNATED LEVEL MUST ANNUALLY COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM. ALL PVS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION C, LINE 19 PVS'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. FORM 990, PART XI, LINE 9: FOR THE YEAR ENDED DECEMBER 31, 2018, THE ORGANIZATION ADOPTED THE FINANCIAL ACCOUNTING STANDARDS BOARD'S ACCOUNTING STANDARDS UPDATE (ASU) NO. 2018-08 - NOT-FOR-PROFIT ENTITIES (TOPIC 958): CLARIFYING THE SCOPE AND THE ACCOUNTING GUIDANCE FOR CONTRIBUTIONS RECEIVED AND CONTRIBUTIONS MADE FOR REVENUE TRANSACTIONS. THE UPDATE ASSISTS ENTITIES IN (1) EVALUATING WHETHER TRANSACTIONS SHOULD BE ACCOUNTED FOR AS CONTRIBUTIONS (NONRECIPROCAL TRANSACTIONS) OR AS EXCHANGE (RECIPROCAL) TRANSACTIONS AND (2) DETERMINING WHETHER A CONTRIBUTION IS CONDITIONAL. THE PRIMARY EFFECT OF ADOPTION OF THIS ASU FOR THE ORGANIZATION IS THAT CERTAIN AWARDS RECEIVED THAT WERE PREVIOUSLY TREATED AS UNCONDITIONAL ARE NOW TREATED AS CONDITIONAL. AS A RESULT, REVENUE FOR THESE AWARDS IS RECOGNIZED WHEN THE CONDITIONS ARE MET DURING THE AWARD TERM, WHEREAS PREVIOUSLY REVENUE HAD BEEN RECOGNIZED WHEN THE AWARDS WERE AWARDED. PATH HAS ELECTED TO ADOPT THE CHANGES FROM THIS ASU RETROSPECTIVELY TO THE 2017 FINANCIAL STATEMENTS. THE NET EFFECT OF THIS CHANGE IS PRESENTED AS AN OTHER CHANGE IN NET ASSETS. -52,243,651. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH DRUG SOLUTIONS 280 UTAH AVENUE SUITE 250 SAN FRANCISCO CA 94080 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0